Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-04-22
1999-07-06
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 172, A61K 3170, C07H 1520
Patent
active
059197692
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel fucose derivative, a drug containing the same as an active ingredient, and an intermediate for producing the same. More particularly, the present invention relates to a novel compound of the formula (I): ##STR3## wherein X.sup.1 is a group of one of the following formulae (1), (2) and (3): ##STR4## R.sup.1 is a branched long chain alkyl group, R.sup.2 is --CONHR.sup.3, a carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and R.sup.3 is a lower alkyl group or a phenyl group, or a pharmaceutically acceptable salt thereof, which is useful as a compound inhibiting the binding of selectin, a cell adhesion molecule, to sialyl Lewis X (hereinbelow, referred to as sialyl Le.sup.X) sugar chain.
The present invention also relates to an intermediate for producing these novel fucose derivatives or a pharmaceutically acceptable salt thereof.
BACKGROUND ART
Recently, much attention has been paid to the role of selectin which is a cell adhesion molecule in various inflammatory diseases. For example, there have been known some kinds of selectin, e.g., E-selectin (occasionally referred to as ELAM-1), P-selectin (occasionally referred to as GMP-140), L-selectin (occasionally referred to as LECAM-1), etc., and these selectins are present on various cells in the progress of inflammatory response.
For example, E-selectin is an adhesion molecule which is mainly induced on the surface of vascular endothelial cells by stimuli with TNF.alpha. (tumor necrosis factor .alpha.), IL-1 (interleukin 1); P-selectin is an adhesion molecule which is mainly induced at platelet .alpha.-granules or Wiebel-Pallade corpuscle of vascular endothelial cells by the stimuli with thrombin, histamine, etc.; and L-selectin is an adhesion molecule which is present on the surface of leucocyte cells.
Generally, cell infiltration is one of the most important symptoms of inflammation, and it is known that white blood cells in the blood bind to the vascular endothelial cells, and then infiltrate into the affected tissue. Prior to the attachment of white blood cells to vascular endothelial cells, the white blood cells roll along the endothelium, which is called "rolling". The "rolling" is the important event as the first stage of cell infiltration, and it is mediated by the binding of the above-mentioned various selectins to sialyl Le.sup.X sugar chain (ligand of selectin) which is present on the surface of white blood cells.
Therefore, there have been tried treatments of various inflammatory diseases by blocking the binding of selectin to sialyl Le.sup.X oligosaccharide, and inhibiting adhesion of white blood cells. As a selectin ligand (counter ligand) inhibiting the adhesion of white blood cells, there are known peptide counter ligands (e.g., WO 95/04751, WO 95/10296, etc.) in addition to some sialyl Le.sup.X derivatives, and these ligands are compounds having only fucose as a sugar moiety.
Drugs containing a counter ligand of selectin as an active ingredient (selectin inhibitors) can suppress and control various inflammatory diseases such as inflammatory dermatitis (e.g., atopic dermatitis, contact hypersensitivity, photodermatosis, etc.), autoimmune chronic diseases (e.g. rheumatoid arthritis, chronic thyroiditis, etc.), and the like, by inhibiting the adhesion of white blood cells.
Besides, in case of ischemia-reperfusion injury, it has been reported that various selectins participate in the endothelial cell injures caused by neutrophil infiltration (cf., stroke, 25, 202-210 (1994)). In fact, it has been reported that ischemia-reperfusion injury in reflow animal models is suppressed by a sialyl Le.sup.X derivative which is a counter ligand of selectin (cf., J. Clin. Invest., 93, 1140-1148 (1994)!. Therefore, a selectin inhibitor can show inhibitory effects on ischemia-reperfusion injury as well (cf., U.S. Pat. No. 5,444,050).
DISCLOSURE OF INVENTION
An object of the present invention is to provide a novel fucose derivative or a pharmaceutically acceptable salt thereof, which in
REFERENCES:
patent: 5444050 (1995-08-01), Kogan et al.
Buerke, M. et al., "Sialyl Lewis.sup.x -Containing Oligosaccharide Attenuates Myocardial Reperfusion Injury in Cats", J. Clin. Invest., 93:1140-1148 (Mar. 1994).
Okada, Y. et al., "P-Selectin and Intercellular Adhesion Molecule-1 Expression After Focal Brain Ischemia and Reperfusion", Stoke, 25(1):202-211 (Jan. 1994).
Achiha Toshio
Kiyoi Takao
Kondo Hirosato
Kurokawa Kiriko
Moriyama Hideki
Kanebo Ltd
Lambkin Deborah C.
LandOfFree
Fucose derivatives, drugs containing the same as active ingredie does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fucose derivatives, drugs containing the same as active ingredie, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fucose derivatives, drugs containing the same as active ingredie will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899090